Tissue engineered skin substitutes emerged in the 1980s. Development was motivated primarily by the critical need for early coverage of extensive burn injuries in patients with insufficient sources of autologous skin for grafting. Since then, skin substitutes have been widely used to address the prevalent problem of chronic wounds associated with non-burn etiologies (such as hard-to-heal, chronic, open wounds in patients with diabetes mellitus and /or arteriosclerosis). The annual incidence of serious burns in the United States is estimated at 70,000. The prevalence of venous leg ulcers is between 600,000 and 1,500,000; and 15 to 20 percent of people with diabetes eventually suffer a chronic foot wound. The direct cost, in the US, of dressings alone for all these conditions has been estimated at over $5 billion per year.
Use of Skin Substitutes--BurnSurgery.org
New Skin for Old Developments in Biological Skin Substitutes; Arch Dermatol. 1998;134:344-349
Current Concepts in Wound Healing; Plastic and Reconstructive Surgery Supplement; Vol 117, No 75, June 2006.
Wound Healing: Skin Substitutes and Blood-Derived Growth Factors --Medical Policy BCBS